ARTBIO develops alpha radioligand therapies (ARTs) and is advancing multiple pipeline programs with a lead program, AB001, currently in first-in-human trials. The company’s AlphaDirect™ proprietary generator technology enables flexible, distributed production of clinical-grade lead-212 to support dosing and a resilient supply chain. ARTBIO plans to expand its manufacturing network and supply-chain infrastructure to support global clinical trials and eventual commercialization. Proceeds from the recent financing will accelerate AB001 through Phase II and move additional undisclosed programs toward IND readiness. The company highlights a scientific legacy tied to the University of Oslo and Norway’s Radium Hospital and operates from Cambridge, Massachusetts and Oslo, Norway. ARTBIO is a clinical-stage radiopharmaceutical company based in Cambridge, MA and Basel, Switzerland, focused on developing alpha radioligand therapies for cancer. Led by CEO Emanuele Ostuni, Ph.D., the company selects Pb212 as its chosen alpha precursor and pairs it with tumor-specific targets to create its alpha radioligand therapies (ARTs). Its proprietary AlphaDirect™ Pb212 isolation technology enables a distributed manufacturing approach for production and delivery of ARTs. ARTBIO is advancing three pipeline programs with lead candidate AB001 currently in first-in-human trials for prostate cancer. The company intends to use the Series A proceeds to solidify AlphaDirect™, expand its distributed manufacturing network, advance AB001 in the clinic, and further its pipeline. Concurrent with the Series A closing it appointed Philippe Dasse as Chief Technical Officer and Daniel Rossetto as Head and Senior Vice President of Supply Chain and External Manufacturing.

Total raised

$222M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2025